{"title":"Impact of pharmaceutical care interventions on antidepressants adherence and clinical outcomes in depressed patients: A systematic review","authors":"Nirmal Raj Marasine , Sabina Sankhi , Shishir Paudel , Anisha Chalise , Rajendra Lamichhane","doi":"10.1016/j.rcsop.2025.100644","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Medication non-adherence, impaired health-related quality of life (HRQoL), increased depression severity, and patient dissatisfaction are common challenges among patients with depression. This systematic review aimed to evaluate the impact of pharmaceutical care interventions (PCIs) on antidepressant adherence, HRQoL, depression severity, and patient satisfaction.</div></div><div><h3>Methods</h3><div>This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A comprehensive search was conducted across PubMed, EMBASE, Web of Science, Scopus, PsycINFO, and CINAHL for randomized controlled trials (RCTs) published between 2000 and 2024. Studies evaluating pharmacist-led pharmaceutical care interventions aimed at improving antidepressant use and related outcomes were included. Data extraction and risk of bias assessment were performed using standardized forms and the Cochrane Collaboration's Risk of Bias tool.</div></div><div><h3>Results</h3><div>Fifteen RCTs met the inclusion criteria. Common intervention strategies included patient education, counseling, telephone follow-ups, and drug monitoring. Nine studies reported statistically significant improvements in antidepressant adherence. Of the three studies assessing HRQoL, one demonstrated significant improvement. Four of thirteen studies showed a significant reduction in depression severity, and three of five studies reported increased patient satisfaction in the intervention group compared to controls<strong>.</strong></div></div><div><h3>Conclusion</h3><div>Pharmaceutical care interventions, particularly patient education and counseling, contribute meaningfully in improving antidepressant adherence and related patient outcomes. However, findings across studies are inconsistent due to variability in intervention components, measurement tools, delivery methods, and outcome measures. Further research should focus on well-designed, large randomized trials with standardized, therory-based interventions.</div></div>","PeriodicalId":73003,"journal":{"name":"Exploratory research in clinical and social pharmacy","volume":"20 ","pages":"Article 100644"},"PeriodicalIF":1.8000,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Exploratory research in clinical and social pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S266727662500085X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Medication non-adherence, impaired health-related quality of life (HRQoL), increased depression severity, and patient dissatisfaction are common challenges among patients with depression. This systematic review aimed to evaluate the impact of pharmaceutical care interventions (PCIs) on antidepressant adherence, HRQoL, depression severity, and patient satisfaction.
Methods
This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A comprehensive search was conducted across PubMed, EMBASE, Web of Science, Scopus, PsycINFO, and CINAHL for randomized controlled trials (RCTs) published between 2000 and 2024. Studies evaluating pharmacist-led pharmaceutical care interventions aimed at improving antidepressant use and related outcomes were included. Data extraction and risk of bias assessment were performed using standardized forms and the Cochrane Collaboration's Risk of Bias tool.
Results
Fifteen RCTs met the inclusion criteria. Common intervention strategies included patient education, counseling, telephone follow-ups, and drug monitoring. Nine studies reported statistically significant improvements in antidepressant adherence. Of the three studies assessing HRQoL, one demonstrated significant improvement. Four of thirteen studies showed a significant reduction in depression severity, and three of five studies reported increased patient satisfaction in the intervention group compared to controls.
Conclusion
Pharmaceutical care interventions, particularly patient education and counseling, contribute meaningfully in improving antidepressant adherence and related patient outcomes. However, findings across studies are inconsistent due to variability in intervention components, measurement tools, delivery methods, and outcome measures. Further research should focus on well-designed, large randomized trials with standardized, therory-based interventions.
研究背景:药物依从性差、健康相关生活质量(HRQoL)受损、抑郁严重程度增加和患者不满是抑郁症患者面临的共同挑战。本系统综述旨在评估药学服务干预(PCIs)对抗抑郁药物依从性、HRQoL、抑郁严重程度和患者满意度的影响。方法本综述遵循系统评价和荟萃分析的首选报告项目(PRISMA)指南。综合检索PubMed、EMBASE、Web of Science、Scopus、PsycINFO和CINAHL,检索2000年至2024年间发表的随机对照试验(rct)。评估以药剂师为主导的旨在改善抗抑郁药使用和相关结果的药学服务干预措施的研究被纳入其中。使用标准化表格和Cochrane协作的偏倚风险工具进行数据提取和偏倚风险评估。结果15项rct符合纳入标准。常见的干预策略包括患者教育、咨询、电话随访和药物监测。9项研究报告了抗抑郁药物依从性的统计学显著改善。在评估HRQoL的三项研究中,一项研究显示有显著改善。13项研究中有4项显示抑郁症严重程度显著降低,5项研究中有3项报告说,与对照组相比,干预组的患者满意度提高。结论药学服务干预,特别是患者教育和咨询,对改善抗抑郁依从性和相关患者预后有重要作用。然而,由于干预成分、测量工具、交付方法和结果测量的可变性,研究结果不一致。进一步的研究应侧重于设计良好的大型随机试验,采用标准化的、基于理论的干预措施。